Navigation Links
Essilor Cancels 700,000 Shares
Date:11/22/2007

CHARENTON-LE-PONT, France, November 22 /PRNewswire-FirstCall/ -- Essilor yesterday cancelled 700,000 shares as part of its commitment to shareholders to offset the dilutive impact of stock option and performance share plans.

At the end of 2006, Essilor's Board of Directors authorized the granting of 930,740 stock options and 576,264 performance shares to employees. These grants will potentially lead to the issuance of up to 1,507,004 new shares between 2009 and 2011, depending on Essilor's share performance. They reflect Essilor's commitment to allowing employees to share the benefits of business growth.

Essilor is also committed to protecting its shareholders' interests, by implementing share buyback programs.

In line with this policy, since the beginning of the second half the Company has bought back and canceled 400,000 convertible bonds due 2010 - reducing by 800,000 the number of shares to be issued in the event that the bonds are converted - and has canceled 700,000 shares held in treasury, in order to offset the dilutive impact of these grants.

In addition, 500,000 shares were bought back in September and a further 500,000 during the current month.

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Airwear(R), Essilor(R) and Definity(TM)brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 244 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index (ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EF FP).

Investor Relations and Financial Communications

Veronique Gillet

Phone: +33(0)1-49-77-42-16

http://www.essilor.com


'/>"/>
SOURCE Essilor
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Essilors 2007 Third-Quarter Report
2. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
3. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
4. Neuralstem Shares Accepted for Trading on Amex(R)
5. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
6. Discas, Inc. Sells Shares to SNX Organic Fertilizers, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, the company continues ... Images such as the Fonz in a lab coat and Large Marge have been posted ... field. , FireflySci is proud to be the only cuvette manufacturer is the ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
(Date:8/27/2015)... SAN DIEGO , Aug. 27, 2015 ... second annual meeting of the Japan Society of HTLV-1, ... Science Institute Auditorium. The purpose of the Society is ... well as the development of medical technology and research ... health and welfare. "HUYA is proud to ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... Pharmaceuticals, Inc ., a late-stage epigenetics oncology company, announced today that ... BIO Investor Forum , San Francisco, CA, ... on Target , Panel Discussion: HDACi and Their Progress in the ... Annual Healthcare Conference , New York, NY, November 16, 1:30 PM ...
... Metabolomx, a diagnostic company focused on breath analysis ... was awarded a Small Business Innovation Research (SBIR) contract ... combined Phase I/II Fast-Track contract will support the research ... lung cancer. Metabolomx, proprietary technology is designed ...
... 2011 Amsterdam Molecular Therapeutics (Euronext: AMT), ... today announced that the European Medicines Agency,s (EMA) Committee ... its earlier opinion that Glybera (alipogene tiparvovec) is not ... to the positive recommendation of CHMP Rapporteurs, the Scientific ...
Cached Biology Technology:Syndax Pharmaceuticals to Present at Upcoming Fall Conferences 2Metabolomx Awarded $1.14 Million SBIR Grant from National Cancer Institute for Breath Analysis Test of Lung Cancer 2Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 2Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application 3
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... a disease mechanism that links hereditary amyotrophic lateral sclerosis to ... to a possible therapeutic target. The findings are reported ... Neuroscience . ALS is an adult-onset disease that causes ... five years of diagnosis. Scott Brady, professor and ...
... Long-awaited advances in reducing the cost of certain ... quietly led to production of super-strong forms of the ... story of the current issue of Chemical & ... forms of polyethylene have led to availability of stronger, ...
... of cigarette smoke, tobacco companies have introduced "harm reduction ... But stem cell scientists at the University of California, ... off the tip of a cigarette) from harm reduction ... than sidestream smoke from a conventional brand. ...
Cached Biology News:Link between 2 forms of ALS suggests drug target 2Link between 2 forms of ALS suggests drug target 3Harm reduction cigarettes can be more harmful than conventional brands, researchers report 2
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse polyclonal antibody to GRID2 - glutamate receptor, ionotropic, delta 2...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Biology Products: